ArticleBiochemistry and biophysics reports2025
Illuminating the therapeutic potential of Schisandrin a against rheumatoid arthritis by targeting ferroptosis: An integrated bioinformatics and experimental study.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and hyperplasia of the synovial membrane. This study aimed to elucidate the anti-inflammatory mechanisms of Schisandrin A (SCHA), a bioactive component from Schisandra chinensis, on RA fibroblast-like synoviocytes (FLSs). Integrated bioinformatics analysis was performed on transcriptomic datasets from RA and normal FLSs as well as SCHA-treated RA FLSs. Enrichment analysis revealed that differentially expressed genes between groups were significantly enriched in the ferroptosis pathway, suggesting SCHA may exert anti-inflammatory effects by inhibiting ferroptosis. Protein-protein interaction network analysis identified Txnrd1, lpcat3 and slc7a11 as key hub genes with pivotal roles in mediating SCHA's effects, and molecular docking and dynamics simulations demonstrated that SCHA directly binds to these proteins with favorable binding affinities through hydrogen bonds and hydrophobic contacts, with stable complex formation confirmed over 100-ns molecular dynamics trajectories. In lipopolysaccharide (LPS)-induced inflamed RA FLSs, SCHA significantly decreased pro-inflammatory cytokines IL-6, TNF-α and IL-1β at both protein and mRNA levels, restored antioxidant enzymes GSH-Px and SOD levels, and reduced lipid peroxidation product MDA, Fe2+ and ROS levels in a dose-dependent manner Transmission electron microscopy confirmed SCHA's dose-dependent protective effects against ferroptosis-induced mitochondrial damage. Our study demonstrates inhibition of ferroptosis via targeting TXNRD1, LPCAT3 and SLC7A11 mediates the anti-inflammatory effects of SCHA on RA FLSs. These findings reveal a novel mechanism for SCHA's therapeutic potential against RA by modulating ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.